HC Wainwright Issues Pessimistic Estimate for KPTI Earnings

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Analysts at HC Wainwright reduced their FY2025 EPS estimates for shares of Karyopharm Therapeutics in a research note issued to investors on Tuesday, November 4th. HC Wainwright analyst R. Burns now expects that the company will earn ($12.61) per share for the year, down from their previous forecast of ($11.78). HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q4 2025 earnings at ($2.25) EPS, Q1 2026 earnings at ($1.56) EPS, Q3 2026 earnings at ($1.22) EPS, Q4 2026 earnings at ($1.17) EPS and FY2026 earnings at ($5.25) EPS.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($3.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.30) by ($0.52). The firm had revenue of $44.04 million for the quarter, compared to the consensus estimate of $39.56 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS.

Several other equities analysts also recently commented on the company. Robert W. Baird dropped their target price on Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday, October 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Karyopharm Therapeutics in a research note on Wednesday. Piper Sandler reiterated an “overweight” rating and issued a $12.00 price objective (down previously from $15.00) on shares of Karyopharm Therapeutics in a report on Thursday, October 9th. Finally, Royal Bank Of Canada cut their target price on shares of Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating on the stock in a research report on Tuesday. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $15.40.

Karyopharm Therapeutics Stock Down 2.6%

NASDAQ KPTI opened at $5.22 on Thursday. The company has a market cap of $45.26 million, a price-to-earnings ratio of -0.36 and a beta of 0.35. Karyopharm Therapeutics has a twelve month low of $3.51 and a twelve month high of $14.24. The business’s fifty day moving average is $6.22 and its 200 day moving average is $5.40.

Hedge Funds Weigh In On Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in KPTI. T. Rowe Price Investment Management Inc. bought a new stake in Karyopharm Therapeutics in the first quarter valued at approximately $523,000. XTX Topco Ltd bought a new position in Karyopharm Therapeutics during the 2nd quarter worth approximately $56,000. Silverback Asset Management LLC lifted its position in shares of Karyopharm Therapeutics by 40.0% in the 2nd quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock worth $302,000 after purchasing an additional 20,000 shares during the period. Baird Financial Group Inc. acquired a new position in shares of Karyopharm Therapeutics in the 2nd quarter worth approximately $45,000. Finally, Bank of America Corp DE boosted its stake in shares of Karyopharm Therapeutics by 26.8% in the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock valued at $726,000 after purchasing an additional 35,626 shares during the last quarter. 66.44% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).